Objectives. Magnetic resonance spectroscopy (MRS) allows the contents of many metabolites in living tissues to be assessed. There is a good number of studies analyzing MRS data in Alzheimer’s disease (AD), though their results are contradictory. In this regard, there is value in comparing MRS data with fluorodeoxyglucose (FDG) positron emission tomography (PET) results, which assess the functional state of nervous tissue. The present study provides a comparison of MRI scan data in AD and moderate cognitive impairment (MCI) with the characteristics of cerebral glucose metabolism assessed from FDG-PET data. Materials and methods. Multivoxel proton MRS of the supraventricular region was carried out in patients with AD (n = 16) and MCI (n = 14). The following metabolite ratios were determined: NAA/Cr, Cho/Cr, and NAA/Cho (NAA is N-acetylaspartate, Cr is creatine, and Cho is choline). Patients underwent neurological investigation, assessment of cognitive status, and PET scans with FDG. Results. Patients with AD showed decreases in NAA/Cr and Cho/Cr in the white matter of the medial cortex of the supraventricular areas of both hemispheres. The MCI group showed a decrease in the NAA/Cr ratio in only one area of the white matter of the left hemisphere, adjacent to the parietal cortex. Positive correlations were found between NAA/Cr and Cho/Cr with measures of cognitive status and with the rate of glucose metabolism measured from PET data in the frontal, parietal, and temporal areas and the cingulate cortex. Conclusions. The decrease in the NAA/Cr ratio in the supraventricular white matter and the medial cortex in AD and the correlation of this parameter with cognitive test results and cerebral glucose metabolism constitute evidence that it may have diagnostic value, reflecting the severity of cognitive impairments. Assessment of the NAA/Cr ratio should be carried out with consideration of the fact that dementia alters the concentrations of both metabolites (NAA and Cr).
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
M. Tabert, X. Liu, R. Doty, et al., “A 10-item smell identification scale related to risk for Alzheimer’s disease,” Ann. Neurol., 58, No. 1, 155–160 (2005).
G. Verdile, S. Fuller, C. Atwood, et al., “The role of beta amyloid in Alzheimer’s disease: still a cause of everything or the only one who got caught?” Pharmacol. Res., 50, 397–409 (2004).
C. Mathis, N. Mason, B. Lopresti, and W. Klunk, “Development of positron emission tomography β-amyloid plaque imaging agents,” Semin. Nucl. Med., 42, No. 6, 423–432 (2012), https://doi.org/https://doi.org/10.1053/j.semnuclmed.2012.07.001.
P. Trzepacz, P. Yu, J. Sun, K. Schuh, et al., Alzheimer’s Disease Neuroimaging Initiative, “Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer’s dementia,” Neurobiol. Aging, 35, No. 1, 143–151 (2014), https://doi.org/https://doi.org/10.1016/j.neurobiolaging.2013.06.018.
M. Modo and J. Bulte (eds.), Magnetic Resonance Neuroimaging. Methods in Molecular Biology, Springer (2011), https://doi.org/https://doi.org/10.1007/978-1-61737-992-5_9.
P. B. Barker, A. Bizzi, N. De Stefano, et al., Clinical MR Spectroscopy: Techniques and Applications, Cambridge University Press (2009).
K. K. Haga, Y. P. Khor, A. Farrall, and J. M. Wardlaw, “A systematic review of brain metabolite changes, measured with 1H magnetic resonance spectroscopy, in healthy aging,” Neurobiol. Aging, 30, 353–363 (2009), https://doi.org/https://doi.org/10.1016/j.neurobiolaging.2007.07.005.
C. Stagg and D. Rothman (eds.), Magnetic Resonance Spectroscopy. Tools for Neuroscience Research and Emerging Clinical Applications, Elsevier (2014).
N. A. Semenova, T. A. Akhadov, A. V. Petryaikin, et al., “Metabolic impairments and the interaction of metabolic processes in the frontoparietal cortex of the brain in severe craniocerebral trauma. A study using local 1H magnetic resonance spectroscopy,” Biokhimiya, 77, No. 4, 493500 (2012).
H. P. Hetherington, G. F. Mason, J. W. Pan, et al., “Evaluation of cerebral gray and white matter metabolite differences by spectroscopic imaging at 4.1T,” Magn. Reson. Med., 32, No. 5, 565–571 (1994), https://doi.org/https://doi.org/10.1002/mrm.1910320504.
A. Shiino, M. Matsuda, S. Morikawa, et al., “Proton magnetic resonance spectroscopy with dementia,” Surg. Neurol., 39, No. 2, 143–147 (1993), https://doi.org/https://doi.org/10.1016/0090-3019(93)90093-g.
K. Kantarci, R. C. Petersen, and B. F. Boeve, “1H-MR spectroscopy in common dementias,” Neurology, 63, No. 8, 1393–1398 (2004), https://doi.org/https://doi.org/10.1212/01.wnl.0000141849.21256.ac.
H. Wang, L. Tan, H. F. Wang, et al., “Magnetic resonance spectroscopy in Alzheimer’s disease: systematic review and meta-analysis,” J. Alzheimers Dis., 46, No. 4, 1049–1070 (2015), https://doi.org/https://doi.org/10.3233/JAD-143225.
B. B. Frederick, A. Satlin, D. A. Yurgelun-Todd, and P. F. Renshaw, “In vivo proton magnetic resonance spectroscopy of Alzheimer’s disease in the parietal and temporal lobes,” Biol. Psychiatry, 42, No. 2, 147–150 (1997), https://doi.org/https://doi.org/10.1016/s0006-3223(97)00242-4.
A. Bitsch, H. Bruhn, V. Vougioukas, et al., “Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy,” AJNR Am. J. Neuroradiol., 20, No. 9, 1619–1627 (1999).
F. Jessen, W. Block, and F. Traber, “Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD,” Neurology, 55, No. 5, 684–688 (2000), www. ajnr.org/content/20/9/1619, acc. May 15, 2018.
W. Huang, G. E. Alexander, L. Chang, et al., “Brain metabolite concentration and dementia severity in Alzheimer’s disease: a (1)H MRS study,” Neurology, 57, No. 4, 626–632 (2001), https://doi. org/https://doi.org/10.1212/wnl.57.4.626.
A. Pfefferbaum, E. Adalsteinsson, D. Spielman, et al., “In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging,” Magn. Reson. Med., 41, No. 2, 276–284 (1999), https://doi. org/10.1002/(sici)1522-2594(199902)41:2<276::aid-mrm10>3.3.co.
K. R. Krishnan, H. C. Charles, P. M. Doraiswamy, et al., “Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease,” Am. J. Psychiatry, 160, No. 11, 2003–2011 (2003), https://doi.org/https://doi.org/10.1176/appi.ajp.160.11.2003.
S. Chantal, M. Labelle, R. W. Bouchard, et al., “Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease,” Arch. Neurol., 59, No.6, 955962 (2002), https://doi.org/https://doi.org/10.1001/archneur.59.6.955.
S. Tumati, S. Martens, and A. Aleman, “Magnetic resonance spectroscopy in mild cognitive impairment: systematic review and meta-analysis,” Neurosci. Biobehav. Rev., 37, No. 10, Pt 2, 2571–2586 (2013), https://doi.org/https://doi.org/10.1016/j.neubiorev.2013.08.004.
B. Zhang, T. J. Ferman, B. F. Boeve, et al., “MRS in mild cognitive impairment: early differentiation of dementia with Lewy bodies and Alzheimer’s disease,” J. Neuroimaging, 25, No. 2, 269–274 (2015), https://doi.org/https://doi.org/10.1111/jon.12138.
K. Kantarci, D. S. Knopman, D. W. Dickson, et al., “Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements,” Radiology, 248, No. 1, 210–220 (2008), https://doi.org/https://doi.org/10.1148/radiol.2481071590.
A. M. N. Coutinho, F. H. G. Porto, P. F. Zampieri, et al., “Analysis of the posterior cingulate cortex with [18F]FDG-PET and Naa/mI in mild cognitive impairment and Alzheimer’s disease: Correlations and differences between the two methods,” Dement. Neuropsychol., 9, No. 4, 385–393 (2015), https://doi.org/https://doi.org/10.1590/1980-57642015DN94000385.
S. V. Medvedev, T. Yu. Skvortsova, and R. N. Krasikova, PET in Russia: Positron Emission Tomography in the Clinic and Physiology, St. Petersburg (2008).
A. A. Bogdan, Yu. G. Khomenko, G. V. Kataeva, and T. N. Trofimova, “Principles of data grouping in assessment of the results of multivoxel spectroscopic investigations of the brain,” Luch. Diagnost. Ter., 4, No. 7, 15–19 (2016).
R. A. Charlton, D. J. McIntyre, F. A. Howe, et al., “The relationship between white matter brain metabolites and cognition in normal aging: The GENIE study,” Brain Res., 1164, 108–116 (2007), https:// doi.org/https://doi.org/10.1016/j.brainres.2007.06.027.
J. M. Allman, N. A. Tetreault, A. Y. Hakeem, et al., “The von Economo neurons in frontoinsular and anterior cingulate cortex,” Ann. N. Y. Acad. Sci., 1225, 59–71 (2011), https://doi.org/https://doi.org/10.1111/j.1749-6632.2011.06011.x.
J. Talairach and P. Tournoux, Co-Planar Stereotactic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging, Thieme, New York (1988).
Statistical Parametric Mapping, www.fi l.ion.ucl.ac.uk/spm/, acc. May 15, 2018.
WFU PickAtlas, www.nitrc.org/projects/wfu_pickatlas/, acc. May 15, 2018.
I. Yakushev, C. Landvogt, H. G. Buchholz, et al., “Choice of reference area in studies of Alzheimer’s disease using positron emission tomography with fluorodeoxyglucose-F18,” Psychiatry Res., 164, No. 2, 143–153 (2008), http://dx.doi.org/https://doi.org/10.1016/j.pscychresns.2007.11.004.
Yu. G. Khomenko, A. A. Bogdan, G. V. Kataeva, and E. M. Chernysheva, “Use of multivoxel magnetic resonance spectroscopy in investigations of patients with cognitive disorders,” Vestn. Stankt- Peterburg. Univ. Ser. 4, Fiz, Khim., 3, No. 1, 82–89 (2016).
N. Schuff, D. L. Amend, D. J. Meyerhoff, et al., “Alzheimer disease: Quantitative H-1 MR spectroscopic imaging of frontoparietal brain,” Radiology, 207, No. 1, 91–102 (1998).
E. A. Gromova, A. A. Bogdan, G. V. Kataeva, et al., “Characteristics of the functional state of brain structures in HIV-infected patients,” Luch. Diagnost., 1, 41–48 (2016).
K. Weissenborn, B. Ahl, D. Fischer-Wasels, et al., “Correlations between magnetic resonance spectroscopy alterations and cerebral ammonia and glucose metabolism in cirrhotic patients with and without hepatic encephalopathy,” Gut, 56, No. 12, 1736–1742 (2007), http:// dx.doi.org/https://doi.org/10.1136/gut.2006.110569.
R. Mielke, H. H. Schopphoff, H. Kugel, et al., “Relation between 1H MR spectroscopic imaging and regional cerebral glucose metabolism in Alzheimer’s disease,” Int. J. Neurosci., 107, No. 34, 233–245 2001), https://doi.org/https://doi.org/10.3109/00207450109150687.
J. O’Neill, J. L. Eberling, N. Schuff, et al., “Method to correlate 1H MRSI and 18FDG-PET,” Magn. Reson. Med., 43, No. 2, 244–50 (2000), https://doi.org/10.1002/(sici)1522-2594(200002)43:2<244:: aid-mrm11>3.3.co.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 119, No. 1, Iss. 1, pp. 51–58, January, 2019.
Rights and permissions
About this article
Cite this article
Khomenko, Y.G., Kataeva, G.V., Bogdan, A.A. et al. Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study. Neurosci Behav Physi 49, 1199–1207 (2019). https://doi.org/10.1007/s11055-019-00858-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-019-00858-1